1 |
Kolev M, Das M, Gerber M, Baver S, Deschatelets P, Markiewski MM. Inside-Out of Complement in Cancer. Front Immunol 2022;13:931273. [DOI: 10.3389/fimmu.2022.931273] [Reference Citation Analysis]
|
2 |
Rahmati Nezhad P, Riihilä P, Knuutila JS, Viiklepp K, Peltonen S, Kallajoki M, Meri S, Nissinen L, Kähäri VM. Complement Factor D Is a Novel Biomarker and Putative Therapeutic Target in Cutaneous Squamous Cell Carcinoma. Cancers (Basel) 2022;14:305. [PMID: 35053469 DOI: 10.3390/cancers14020305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
3 |
Zambrano-Román M, Padilla-Gutiérrez JR, Valle Y, Muñoz-Valle JF, Valdés-Alvarado E. Non-Melanoma Skin Cancer: A Genetic Update and Future Perspectives. Cancers (Basel) 2022;14:2371. [PMID: 35625975 DOI: 10.3390/cancers14102371] [Reference Citation Analysis]
|
4 |
Revel M, Daugan MV, Sautés-Fridman C, Fridman WH, Roumenina LT. Complement System: Promoter or Suppressor of Cancer Progression? Antibodies (Basel) 2020;9:E57. [PMID: 33113844 DOI: 10.3390/antib9040057] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
5 |
Lawal B, Tseng SH, Olugbodi JO, Iamsaard S, Ilesanmi OB, Mahmoud MH, Ahmed SH, Batiha GE, Wu ATH. Pan-Cancer Analysis of Immune Complement Signature C3/C5/C3AR1/C5AR1 in Association with Tumor Immune Evasion and Therapy Resistance. Cancers (Basel) 2021;13:4124. [PMID: 34439277 DOI: 10.3390/cancers13164124] [Reference Citation Analysis]
|